Mohit K. Turagam

Mohit K. Turagam

Auto-generated profile, based on publicly available information

Mohit K. Turagam

Icahn School of Medicine at Mount Sinai , New York, NY

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Circulation
Verified
Journal Article
Closed access
MTMohit K. Turagam
Mohit K. Turagam
PNPetr Neuzil
Petr Neuzil
BSBoris Schmidt
Boris Schmidt
TRTobias Reichlin
Tobias Reichlin
KNKars Neven
Kars Neven
VRVivek Y. Reddy
Vivek Y. Reddy
Background: Pulsed field ablation is a novel nonthermal cardiac ablation modality using ultra-rapid electrical pulses to cause cell death by a mechanism of irreversible electroporation. Unlike the traditional ablation energy sources, pulsed field ablation has demonstrated significant preferentiality to myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety and effectiveness remain unknown in usual clinical care. Methods: MANIFEST-PF (Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation) is a retrospective, multinational, patient-level registry wherein patients at each center were prospectively included in their respective center registries. The registry included all patients undergoing postapproval treatment with a multielectrode 5-spline pulsed field ablation catheter to treat atrial fibrillation (AF) between March 1, 2021, and May 30, 2022. The primary effectiveness outcome was freedom from clinical documented atrial arrhythmia (AF/atrial flutter/atrial tachycardia) of ≥30 seconds on the basis of electrocardiographic data after a 3-month blanking period (on or off antiarrhythmic drugs). Safety outcomes included the composite of acute (7 days) major adverse events. Results: At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA 2 DS 2 -VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289–421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%–80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P =0.001). Acute major adverse events occurred in 1.9% of patients. Conclusions: In this large observational registry of the postapproval clinical use of pulsed field technology to treat AF, catheter ablation using pulsed field energy was clinically effective in 78% of patients with AF.

8 July 2025 in Circulation
Verified
Journal Article
Open access
VRVivek Y. Reddy
Vivek Y. Reddy
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
BSBoris Schmidt
Boris Schmidt
JAJason G Andrade
Jason G Andrade
DNDevi Nair
Devi Nair
MMMoussa Mansour
Moussa Mansour
BACKGROUND: There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter. METHODS: Patients with PerAF underwent PVI and posterior wall ablation with the pentaspline PFA catheter and cavotricuspid isthmus with a novel focal-linear PFA catheter after intravenous nitroglycerin prophylaxis. Patients were followed up for 1 year with continuous rhythm monitoring after ablation with insertable cardiac monitors to emulate traditional intermittent monitoring for the primary efficacy end point and to examine atrial arrhythmia (AA) burden and episode duration. RESULTS: This 255-patient cohort (age, 66.7±9.3 years; female, 29%; CHA 2 DS 2 -VASc score, 2.4±1.4; body mass index, 30.9±5.3 kg/m 2 ; left atrium diameter, 4.3±0.6 cm) underwent PVI plus posterior wall ablation (99.6%/100% acute success); a subpopulation (n=141; 55.3%) also received cavotricuspid isthmus PFA, with 98.6% achieving bidirectional block without complications (ST-segment changes, ventricular fibrillation). Cavotricuspid isthmus ablation took 8±13 minutes, using 18±6 pulsed field applications and 4±2 mg IV nitroglycerin. The total procedure and atrial dwell times were 105±36 and 59±24 minutes, respectively. Mimicking traditional monitoring, freedom from AA was 73.4% with adverse events in 2.4%, both meeting prespecified end-point criteria. Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full insertable cardiac monitor data revealed freedom from AA of ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort. Both an AA burden >0.1% and longest episode duration >1 hour were predictive of increased health care use. One-year procedural effectiveness was 71.6% and 70.0% using the thresholds of ≤0.1% burden and <1 hour duration, respectively. CONCLUSIONS: In Phase 2 of ADVANTAGE AF, the first multicenter PerAF study of PFA with continuous rhythm monitoring: (1) cavotricuspid isthmus ablation with nitroglycerin prophylaxis was safe and effective, (2) PVI plus posterior wall ablation was safe and effective, and (3) an AA burden <0.1% and AA episode <1 hour duration were end points associated with the lowest health care use. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05443594.

17 January 2025 in EP Europace
Verified
Journal Article
Open access
USUniv.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Univ.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
MTMohit K Turagam
Mohit K Turagam
PMPhilippe Maury
Philippe Maury
YBYuri Blaauw
Yuri Blaauw
PVPepijn van der Voort
Pepijn van der Voort
VRVivek Y Reddy
Vivek Y Reddy
Aims: Initial clinical studies of pulsed field ablation (PFA) to treat atrial fibrillation (AF) indicated a >90% durability rate of pulmonary vein isolation (PVI). However, these studies were largely conducted in single centres and involved a limited number of operators. We aimed to describe the electrophysiological findings and outcomes in patients undergoing repeat ablation after an initial PF ablation for AF. Methods and results: In the MANIFEST-REDO study, we investigated patients who underwent repeat ablation due to clinical recurrence—AF or atrial tachycardia (AT)—following first-ever PVI with a pentaspline PFA catheter (Farawave, Boston Scientific Inc.). At 22 centres, 427 patients (age 64 ± 11 years; 37% female) were included. Of note, the recurrent arrhythmia leading to the repeat ablation was paroxysmal AF (51%), persistent AF (30%), or AT (19%). At the repeat procedure, the PV reconnection rates were 30% (left superior pulmonary vein), 28% (left inferior pulmonary vein), 33% (right superior pulmonary vein), and 32% (right inferior pulmonary vein). In 45% of patients, all PVs were durably isolated at the beginning of the repeat procedure, with the previous use of any imaging or mapping modality being univariately associated with durable PVI. After a post-redo follow-up period of 284 (90–366) days, the primary effectiveness endpoint (freedom from documented AF/AT lasting ≥30 s after 3-month blanking without class I/III antiarrhythmic drugs or symptoms) was achieved in 65% of patients, with significant differences between groups (PAF 65% vs. PersAF 56% vs. AT 76%; P = 0.04). Persistent AF as recurrent arrhythmia after the initial PFA ablation predicted AT/AF recurrence after repeat ablation [hazard ratio 1.241 (95% confidence interval 1.534–1.005); P = 0.045]. The procedural complication rate was 2.8%. Conclusion: In repeat procedures for AF/AT performed after an index procedure with PFA for AF, PV reconnections are not uncommon. Repeat procedures can be performed safely and with an acceptable subsequent success rate.

1 March 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
JJJose A. Joglar
Jose A. Joglar
EWElaine Y. Wan
Elaine Y. Wan
MCMina K. Chung
Mina K. Chung
AGAlejandra Gutierrez
Alejandra Gutierrez
MSMark S. Slaughter
Mark S. Slaughter
RGRakesh Gopinathannair
Rakesh Gopinathannair
Orthotropic heart transplantation remains the most effective therapy for patients with end-stage heart failure, with a median survival of ≈13 years. Yet, a number of complications are observed after orthotropic heart transplantation, including atrial and ventricular arrhythmias. Several factors contribute to arrhythmias, such as autonomic denervation, effect of the surgical technique, acute and chronic rejection, and transplant vasculopathy among others. To minimize risk of future arrhythmias, the bicaval technique and minimizing ischemic time are current surgical standards. Sinus node dysfunction is the most common indication for early (within 30 days) pacemaker implantation, whereas atrioventricular block incidence increases as time from transplant increases. Atrial fibrillation can occur in the first few weeks following transplantation but is uncommon in the long term unless secondary to a precipitant such as acute rejection. The most common atrial arrhythmias are atrial flutters, which are mainly typical, but atypical circuits can be observed such as those that involve the remnant donor atrium in regions immediately adjacent to the atrioatrial anastomosis suture line. Choosing the appropriate pharmacological therapy requires careful consideration due to the potential interaction with immunosuppressive agents. Despite historical concerns, adenosine is effective and safe at reduced doses if administered under cardiac monitoring. Catheter ablation has emerged as an effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of atypical flutter circuits. Cardiac allograft vasculopathy is an important risk factor for sudden cardiac death, yet the role of prophylactic implantable cardioverter-defibrillator implant for sudden death prevention is unclear. Current indications for implantable cardioverter-defibrillator implantation are as in the nontransplant population. A number of questions for future research are posed.

1 June 2020 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
VAVarunsiri Atti
Varunsiri Atti
MTMohit K. Turagam
Mohit K. Turagam
JGJalaj Garg
Jalaj Garg
SKScott Koerber
Scott Koerber
AAAakash Angirekula
Aakash Angirekula
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy

29 November 2011 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
PVPoonam Velagapudi
Poonam Velagapudi
MTMohit Turagam
Mohit Turagam
TLThomas Laurence
Thomas Laurence
AKAbraham Kocheril
Abraham Kocheril